Publications by authors named "Daniel Budman"

Claim this Profile
T
The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
Cristina M Ghiuzeli, Miroslav Stýblo, Jesse Saunders, Anthony Calabro, Daniel Budman

Leuk Lymphoma· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715).
Dyda Dao, Tyler Zemla, Aminah Jatoi, Rachel A Freedman, Arti Hurria, Daniel Budman

Oncologist· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.
Karie Runcie, Daniel R Budman, Veena John, Nagashree Seetharamu

Mol Med· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitors in lung cancer: an update.
Kevin Sullivan, Isabel Preeshagul, Daniel Budman, Nagashree Seetharamu

Future Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitors in lung cancer: past, present and future.
Nagashree Seetharamu, Daniel R Budman, Kevin M Sullivan

Future Oncol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
Kelly-Anne Phillips, Meredith M Regan, Karin Ribi, Prudence A Francis, Fabio Puglisi, Daniel R Budman

Br J Cancer· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Iuliana Shapira, Annette Lee, Reena Vora, Daniel R Budman

Crit Rev Oncol Hematol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profile of panobinostat and its potential for treatment in solid tumors: an update.
Madhurima Anne, Daniel Sammartino, Myra F Barginear, Daniel Budman

Onco Targets Ther· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving use of arsenic in pharmacotherapy of malignant disease.
Athena Kritharis, Thomas P Bradley, Daniel R Budman

Ann Hematol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating molecular biology into clinical practice.
Myra F Barginear, Daniel R Budman

J Clin Oncol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.
Myra F Barginear, Veena John, Daniel R Budman

Mol Med· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial.
Myra F Barginear, Richard J Gralla, Thomas P Bradley, Syed S Ali, Iuliana Shapira, Daniel R Budman

Support Care Cancer· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Daniel R Budman, Anthony Calabro, Lisa Rosen, Martin Lesser

Anticancer Drugs· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.
Daniel R Budman, Julia Tai, Anthony Calabro, Veena John

Invest New Drugs· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.
Mary Leung, David Rosen, Scott Fields, Alessandra Cesano, Daniel R Budman

Mol Med· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging role of small ribonucleic acids in gastrointestinal tumors.
Iuliana Shapira, Keith Sultan, Bhoomi Mehrotra, Daniel R Budman

Crit Rev Oncol Hematol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia.
Steven L Allen, Jonathan E Kolitz, Ante S Lundberg, John M Bennett, Robert L Capizzi, Daniel R Budman

Leuk Res· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant chemotherapy for early breast cancer in the elderly.
Mary Leung, Iulianna Shapira, Thomas Bradley, Daniel R Budman

Curr Treat Options Oncol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Need for inferior vena cava filters in cancer patients: a surrogate marker for poor outcome.
Myra F Barginear, Martin Lesser, Meredith Lukin Akerman, Marianna Strakhan, Iuliana Shapira, Daniel R Budman

Clin Appl Thromb Hemost· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
Lyndsay N Harris, Gloria Broadwater, Maysa Abu-Khalaf, David Cowan, Ann D Thor, Daniel Budman

J Clin Oncol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.
Brian H Kim, Thomas Bradley, Julia Tai, Daniel R Budman

Oncology· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel microtubule-targeting agents - the epothilones.
Kit L Cheng, Thomas Bradley, Daniel R Budman

Biologics· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia.
Anthony Calabro, Julia Tai, Steven L Allen, Daniel R Budman

Anticancer Drugs· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
Michael P DiGiovanna, David F Stern, Susan Edgerton, Gloria Broadwater, Lynn G Dressler, Daniel R Budman

J Clin Oncol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Hyman B Muss, Donald A Berry, Constance Cirrincione, Daniel R Budman, I Craig Henderson

J Clin Oncol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis